Pharmaceutical giant Eli Lilly is executing a simultaneous two-front strategy to solidify its commanding position in the multi-billion dollar weight-loss drug market. As the company takes aggressive legal action in the United States against modified versions of its blockbuster drug, it is also channeling billions into strengthening its Asian supply chain. A new pill nearing U.S. regulatory approval sits at the heart of this coordinated approach.
Billions Poured into Supply Ahead of Key FDA Verdict
Concurrently with defending its current market share, Eli Lilly is preparing for its next-generation obesity treatments. The firm has revealed plans to invest $3 billion to establish a local production and supply network in China. This move elevates the company’s total investment commitments in the country to nearly $6 billion.
The focal point of this expansion is Orforglipron, a daily GLP-1 pill. The U.S. Food and Drug Administration (FDA) is expected to rule on its approval on April 10. To prevent supply shortages from the outset, the pharmaceutical leader has already manufactured $1.5 billion worth of inventory.
This aggressive expansion is supported by robust financial projections and analyst confidence:
– 2025 Revenue Forecast: $65.18 billion (a 44.7 percent increase)
– 2025 Profit Forecast: $20.64 billion (a 94.9 percent surge)
– Revised Price Target: Wolfe Research has raised its target to $1,325 from $1,250.
Should investors sell immediately? Or is it worth buying Eli Lilly?
A Strategic Warning on Unregulated Compounds
In a separate but related maneuver, Eli Lilly issued a formal public warning in the U.S. on Thursday concerning altered versions of its weight-loss medication Zepbound. The company identified that pharmacies and telehealth providers are frequently compounding the active ingredient, tirzepatid, with vitamin B12 to create their own formulations. Internal testing confirmed significant impurities in all samples examined, resulting from chemical reactions. Eli Lilly stated that the long-term health consequences of these unregulated mixtures remain entirely unknown.
The company has urgently requested the FDA to initiate a nationwide recall of the affected products. This initiative carries significant economic weight: under the brand names Mounjaro and Zepbound, tirzepatid generated approximately $36.5 billion in revenue in 2025. Following the release of the safety concerns, the company’s share price experienced a slight decline, closing at €848.20 on Thursday.
Geopolitical Context and Immediate Horizon
The timing of the China expansion announcement is notable, coming just ahead of a high-level summit between U.S. President Donald Trump and Chinese leader Xi Jinping. This strategic decision adds a geopolitical layer to the supply chain build-out, even as other U.S. pharmaceutical firms bolster domestic production in response to tariff threats.
The coming weeks are pivotal for the company’s near-term trajectory. With the crucial FDA decision for the new weight-loss pill on April 10 and its legal campaign against unapproved copycat products, Eli Lilly is moving decisively to protect its most critical business segment, which currently accounts for 56 percent of its total revenue.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from March 13 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 13.
Eli Lilly: Buy or sell? Read more here...
